Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Psychiatry Reports
Published in: Current Psychiatry Reports 6/2016

01-06-2016 | Complex Medical-Psychiatric Issues (MB Riba, Section Editor)

Ketamine for Treatment of Suicidal Ideation and Reduction of Risk for Suicidal Behavior

Authors: Faryal Mallick, Cheryl B. McCullumsmith

Published in: Current Psychiatry Reports | Issue 6/2016

Login to get access

Abstract

Ketamine, an NMDA receptor antagonist with efficacy as a rapid anti-depressant, has early evidence for action to reduce suicidal ideation. This review will explore several important questions that arise from these studies. First, how do we measure reductions in suicidal ideation that occur over minutes to hours? Second, are the reductions in suicidal ideation after ketamine treatment solely a result of its rapid anti-depressant effect? Third, is ketamine only effective in reducing suicidal ideation in patients with mood disorders? Fourth, could ketamine’s action lead us to a greater understanding of the neurobiology of suicidal processes? Last, do the reductions in depression and suicidal ideation after ketamine treatment translate into decreased risk for suicidal behavior? Our review concludes that ketamine treatment can be seen as a double-edged sword, clinically to help provide treatment for acutely suicidal patients and experimentally to explore the neurobiological nature of suicidal ideation and suicidal behavior.
Literature
1.
DiazGranados N, Ibrahim L, Brutsche N, et al. Rapid resolution of suicidal ideation after a single infusion of an NMDA antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry. 2010;71:1605.PubMedPubMedCentralCrossRef
2.••
Murrough J, Soleimani L, DeWilde K, et al. Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol Med. 2015;45:1–10. A notable study which showed that suicidal ideation was significantly reduced in patients that received ketamine versus those that were given midazolam. CrossRef
3.•
Price RB, Mathew SJ. Does ketamine have anti-suicidal properties? Current status and future directions. CNS Drugs. 2015;29:181–8. This paper reviews the current evidence supporting rapid effects of ketamine in depression and suicide and discusses future directions for prolongation of the acute benefits of ketamine to a clinically beneficial time frame. PubMedPubMedCentralCrossRef
4.•
Reinstatler L, Youssef NA. Ketamine as a potential treatment for suicidal ideation: a systematic review of the literature. Drugs R D. 2015;15:37–43. Six studies and three case reports were reviewed to conclude the preliminary benefit of use of ketamine for acute treatment of depression and suicidal ideation. PubMedPubMedCentralCrossRef
5.••
Rajkumar R, Fam J, Yeo EY, et al. Ketamine and suicidal ideation in depression: jumping the gun? Pharmacol Res. 2015;99:23–35. This review paper looks at the molecular mechanism of ketamine on the brain, evaluates several rodent and human studies and concludes the limitation of ketamine and the need for studies for further evaluation of long term benefits of ketamine.
6.
Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905–17.PubMedCrossRef
7.
8.
Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351–4.PubMedCrossRef
9.
aan het Rot M, Collins KA, Murrough JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;67:139–45.PubMedCrossRef
10.
Connolly KR, Thase ME. Emerging drugs for major depressive disorder. Expert Opin Emerg Drugs. 2012;17:105–26.PubMedCrossRef
11.
Covvey JR, Crawford AN, Lowe DK. Intravenous ketamine for treatment-resistant major depressive disorder. Ann Pharmacother. 2012;46:117–23.PubMedCrossRef
12.
Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010;67:793–802.PubMedPubMedCentralCrossRef
13.
Glazer WM. Ketamine: a fast-acting antidepressant? Behav Healthc. 2010;30:36–7.PubMed
14.
Zarate CA, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856–64.PubMedCrossRef
15.
Zarate CA, Brutsche NE, Ibrahim L, et al. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012;71:939–46.PubMedPubMedCentralCrossRef
16.
Lapidus KA, Levitch CF, Perez AM, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry. 2014;76:970–6.PubMedPubMedCentralCrossRef
17.
Price RB, Nock MK, Charney DS, et al. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry. 2009;66:522–6.PubMedPubMedCentralCrossRef
18.
Larkin GL, Beautrais AL. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol. 2011;14:1127–31.PubMedCrossRef
19.
20.
De Gioannis A, De Leo D. Oral ketamine augmentation for chronic suicidality in treatment-resistant depression. Aust N Z J Psychiatry. 2014;48:686.PubMedCrossRef
21.
Price RB, Iosifescu DV, Murrough JW, et al. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety. 2014;31:335–43.PubMedPubMedCentralCrossRef
22.
Zigman D, Blier P. Urgent ketamine infusion rapidly eliminated suicidal ideation for a patient with major depressive disorder: a case report. J Clin Psychopharmacol. 2013;33:270–2.PubMedCrossRef
23.
Thakurta RG, Das R, Bhattacharya AK, et al. Rapid response with ketamine on suicidal cognition in resistant depression. Indian J Psychol Med. 2012;34:170–5.PubMedPubMedCentralCrossRef
24.••
Ballard ED, Ionescu DF, Vande Voort JL, et al. Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. J Psychiatr Res. 2014;58:161–6. This study evaluates correlation between depression, anxiety and suicidal ideation and concludes that the improvement in suicidal ideation after ketamine infusion is related to but not completely driven by reduction in depression and anxiety. PubMedCrossRef
25.••
Wan LB, Levitch CF, Perez AM, et al. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry. 2015;76:247–52. This study evaluates short and long term side effects of ketamine. PubMedCrossRef
26.••
Ballard ED, Luckenbaugh DA, Richards EM, et al. Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant. J Psychiatr Res. 2015;68:68–73. Study showed reduction in suicidal ideation on various scales at each time point with ketamine versus placebo. PubMedCrossRef
27.
28.
Van Gastel A, Schotte C, Maes M. The prediction of suicidal intent in depressed patients. Acta Psychiatr Scand. 1997;96:254–9.PubMedCrossRef
29.
Heiligenstein JH, Tollefson GD, Faries DE. A double-blind trial of fluoxetine, 20 mg, and placebo in out-patients with DSM-III-R major depression and melancholia. Int Clin Psychopharmacol. 1993;8:247–51.PubMedCrossRef
30.
31.
Casey PR, Dunn G, Kelly BD, et al. Factors associated with suicidal ideation in the general population: five-centre analysis from the ODIN study. Br J Psychiatry. 2006;189:410–5.PubMedCrossRef
32.
Casey P, Dunn G, Kelly BD, et al. The prevalence of suicidal ideation in the general population: results from the Outcome of Depression International Network (ODIN) study. Soc Psychiatry Psychiatr Epidemiol. 2008;43:299–304.PubMedCrossRef
33.
Price RB, Nock MK, Charney DS, et al. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry. 2009;66:522–6.PubMedPubMedCentralCrossRef
34.•
Price RB, Iosifescu DV, Murrough JW, et al. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment‐resistant depression. Depress Anxiety. 2014;31:335–43. This study also demonstrates that suicidal ideation was significantly reduced in patients with TRD with ketamine as opposed to midazolam treatment on evaluation of composite scores of suicidal ideation. PubMedPubMedCentralCrossRef
35.
Beck AT, Brown GK, Steer RA, et al. Suicide ideation at its worst point: a predictor of eventual suicide in psychiatric outpatients. Suicide Life Threat Behav. 1999;29:1–9.PubMed
36.
Horon R, McManus T, Schmollinger J, et al. A study of the use and interpretation of standardized suicide risk assessment: measures within a psychiatrically hospitalized correctional population. Suicide Life Threat Behav. 2013;43:17–38.PubMedCrossRef
37.
Vuorilehto M, Valtonen HM, Melartin T, et al. Method of assessment determines prevalence of suicidal ideation among patients with depression. Eur Psychiatry. 2013.
38.
Linehan MM, Armstrong HE, Suarez A, et al. Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Arch Gen Psychiatry. 1991;48:1060–4.PubMedCrossRef
39.
Patsiokas AT, Clum GA. Effects of psychotherapeutic strategies in the treatment of suicide attempters. Psychotherapy: Theory, Research, Practice. Training. 1985;22:281–90.
40.
Russ MJ, Kashdan T, Pollack S, et al. Assessment of suicide risk 24 hours after psychiatric hospital admission. Psychiatr Serv. 1999;50:1491–3.PubMedCrossRef
41.
Valtonen HM, Suominen K, Mantere O, et al. Prospective study of risk factors for attempted suicide among patients with bipolar disorder. Bipolar Disord. 2006;8:576–85.PubMedCrossRef
42.
Healy D, Barry K, Blow F, et al. Routine use of the Beck Scale for Suicide Ideation in a psychiatric emergency department. Gen Hosp Psychiatry. 2006;28:323–9.PubMedCrossRef
43.
Coric V, Stock EG, Pultz J, et al. Sheehan Suicidality Tracking Scale (Sheehan-STS): preliminary results from a multicenter clinical trial in generalized anxiety disorder. Psychiatry (Edgmont). 2009;6:26–31.
44.
Alphs L, Canuso C, Williamson D, SIBAT Consortium. The Suicidal Ideation and Behavior Assessment Tool (SIBAT), development of a novel measure of suicidal ideation and behavior and perceived risk. Miami Fl: American Society of Clinical Psychopharmacology (ASCP) annual meeting, poster; 2015.
45.
Brown GK, Currier GW, Jager-Hyman S, et al. Detection and classification of suicidal behavior and nonsuicidal self-injury behavior in emergency departments. J Clin Psychiatry. 2015;76:1397–403.PubMedCrossRef
46.
Beck AT, Kovacs M, Weissman A. Assessment of suicidal intention: the Scale for Suicide Ideation. J Consult Clin Psychol. 1979;47:343–52.PubMedCrossRef
47.
Stefansson J, Nordström P, Jokinen J. Suicide Intent Scale in the prediction of suicide. J Affect Disord. 2012;136:167–71.PubMedCrossRef
48.
Borges G, Angst J, Nock MK, et al. A risk index for 12-month suicide attempts in the National Comorbidity Survey Replication (NCS-R). Psychol Med. 2006;36:1747–57.PubMedPubMedCentralCrossRef
49.
Borges G, Angst J, Nock MK, et al. Risk factors for the incidence and persistence of suicide-related outcomes: a 10-year follow-up study using the National Comorbidity Surveys. J Affect Disord. 2008;105:25–33.PubMedPubMedCentralCrossRef
50.
Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:617–27.PubMedPubMedCentralCrossRef
51.
Nock MK, Borges G, Bromet EJ, et al. Cross-national prevalence and risk factors for suicidal ideation, plans and attempts. Br J Psychiatry. 2008;192:98–105.PubMedPubMedCentralCrossRef
52.
Baca-Garcia E, Diaz-Sastre C, Garcia Resa E, et al. Suicide attempts and impulsivity. Eur Arch Psychiatry Clin Neurosci. 2005;255:152–6.PubMedCrossRef
53.
Brodsky B, Oquendo M, Ellis S, et al. The relationship of childhood abuse to impulsivity and suicidal behavior in adults with major depression. Am J Psychiatry. 2001;158:1871–7.PubMedCrossRef
54.
Dumais A, Lesage AD, Alda M, et al. Risk factors for suicide completion in major depression: a case-control study of impulsive and aggressive behaviors in men. Am J Psychiatry. 2005;162:2116–24.PubMedCrossRef
55.
Kasen S, Cohen P, Chen H. Developmental course of impulsivity and capability from age 10 to age 25 as related to trajectory of suicide attempt in a community cohort. Suicide Life Threat Behav. 2011;41:180–92.PubMedPubMedCentralCrossRef
56.
Oquendo MA, Mann JJ. The biology of impulsivity and suicidality. Psychiatr Clin North Am. 2000;23:11–25.PubMedCrossRef
57.
Oquendo MA, Galfalvy H, Russo S, et al. Prospective study of clinical predictors of suicidal acts after a major depressive episode in patients with major depressive disorder or bipolar disorder. Am J Psychiatry. 2004;161:1433–41.PubMedCrossRef
58.
Zouk H, Tousignant M, Seguin M, et al. Characterization of impulsivity in suicide completers: clinical, behavioral and psychosocial dimensions. J Affect Disord. 2006;92:195–204.PubMedCrossRef
59.
Borges G, Nock M, Haro Abad J, et al. Twelve-month prevalence of and risk factors for suicide attempts in the World Health Organization World Mental Health Surveys. J Clin Psychiatry. 2010.
60.
Mann JJ, Ellis SP, Waternaux CM, et al. Classification trees distinguish suicide attempters in major psychiatric disorders: a model of clinical decision making. J Clin Psychiatry. 2008;69:23.PubMedPubMedCentralCrossRef
61.
Oquendo M, Malone K, Mann J. Suicide: risk factors and prevention in refractory major depression. Depress Anxiety. 1997;5:202–11.PubMedCrossRef
62.
Oquendo MA, Mann JJ. Identifying and managing suicide risk in bipolar patients. J Clin Psychiatry. 2000;62:31–4.
63.
Oquendo MA, Currier D, Liu S, et al. Increased risk for suicidal behavior in comorbid bipolar disorder and alcohol use disorders. J Clin Psychiatry. 2010;71:902.PubMedPubMedCentralCrossRef
64.
Kessler RC, Borges G, Walters EE. Prevalence of and risk factors for lifetime suicide attempts in the National Comorbidity Survey. Arch Gen Psychiatry. 1999;56:617–26.PubMedCrossRef
65.
Bertolote JM, Fleischmann A, De Leo D, et al. Psychiatric diagnoses and suicide: revisiting the evidence. Crisis. 2004;25:147–55.PubMedCrossRef
66.
Bernal M, Haro JM, Bernert S, et al. Risk factors for suicidality in Europe: results from the ESEMED study. J Affect Disord. 2007;101:27–34.PubMedCrossRef
67.
Yen S, Shea MT, Pagano M, et al. Axis I and axis II disorders as predictors of prospective suicide attempts: findings from the collaborative longitudinal personality disorders study. J Abnorm Psychol. 2003;112:375–81.PubMedPubMedCentralCrossRef
68.
Waller SJ, Lyons JS, Costantini-Ferrando MF. Impact of comorbid affective and alcohol use disorders on suicidal ideation and attempts. J Clin Psychol. 1999;55:585–95.PubMedCrossRef
69.
Borges G, Walters EE, Kessler RC. Associations of substance use, abuse, and dependence with subsequent suicidal behavior. Am J Epidemiol. 2000;151:781–9.PubMedCrossRef
70.
Nock MK, Hwang I, Sampson NA, et al. Mental disorders, comorbidity and suicidal behavior: results from the National Comorbidity Survey Replication. Mol Psychiatry. 2010;15:868–76.PubMedPubMedCentralCrossRef
71.
Lahti AC, Holcomb HH, Medoff DR, et al. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport. 1995;6:869–72.PubMedCrossRef
72.
Lahti AC, Koffel B, LaPorte D, et al. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology. 1995;13:9–19.PubMedCrossRef
73.
Wilcox HC, Conner KR, Caine ED. Association of alcohol and drug use disorders and completed suicide: an empirical review of cohort studies. Drug Alcohol Depend. 2004;76:S11–9.PubMedCrossRef
74.
Bisaga A, Popik P, Bespalov AY, et al. Therapeutic potential of NMDA receptor antagonists in the treatment of alcohol and substance use disorders. Expert Opin Investig Drugs. 2000;9:2233–48.PubMedCrossRef
75.
Krupitsky E, Burakov A, Romanova T, et al. Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. J Subst Abuse Treat. 2002;23:273–83.PubMedCrossRef
76.
Krupitsky EM, Burakov AM, Dunaevsky IV, et al. Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. J Psychoactive Drugs. 2007;39:13–9.PubMedCrossRef
77.
78.
Gupta A, Devi LA, Gomes I. Potentiation of μ-opioid receptor-mediated signaling by ketamine. J Neurochem. 2011;119:294–302.PubMedCrossRef
79.
Bell RF, Eccleston C, Kalso E. Ketamine as adjuvant to opioids for cancer pain. A qualitative systematic review. J Pain Symptom Manage. 2003;26:867–75.PubMedCrossRef
80.
Bell HJ, Azubike E, Haouzi P. The “other” respiratory effect of opioids: suppression of spontaneous augmented (“sigh”) breaths. J Appl Physiol. 2011;111:1296–303.PubMedCrossRef
81.
Clark JL, Kalan GE. Effective treatment of severe cancer pain of the head using low-dose ketamine in an opioid-tolerant patient. J Pain Symptom Manage. 1995;10:310–4.PubMedCrossRef
82.
Loftus RW, Yeager MP, Clark JA, et al. Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery. Anesthesiology. 2010;113:639–46.PubMed
83.
Phelps LE, Brutsche N, Moral JR, et al. Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry. 2009;65:181–4.PubMedPubMedCentralCrossRef
84.
Niciu MJ, Luckenbaugh DA, Ionescu DF, et al. Clinical predictors of ketamine response in treatment-resistant major depression. J Clin Psychiatry. 2014;75:e417.PubMedPubMedCentralCrossRef
85.
Dakwar E, Levin F, Foltin RW, et al. The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers. Biol Psychiatry. 2014;76:40–6.PubMedPubMedCentralCrossRef
86.
87.
Smith KM, Larive LL, Romanelli F. Club drugs: methylenedioxy-methamphetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate. American Journal of Health System Pharmacy. 2002;59:1067–76.PubMed
88.
Trujillo KA, Smith ML, Sullivan B, et al. The neurobehavioral pharmacology of ketamine: implications for drug abuse, addiction, and psychiatric disorders. ILAR J. 2011;52:366–78.PubMedPubMedCentralCrossRef
89.
90.
Xu J, Lei H. Ketamine—an update on its clinical uses and abuses. CNS Neurosci Ther. 2014;20:1015–20.PubMedCrossRef
91.
Hassett AL, Aquino JK, Ilgen MA. The risk of suicide mortality in chronic pain patients. Curr Pain Headache Rep. 2014;18:436.PubMedCrossRef
92.
Jimenez-Rodríguez I, Garcia-Leiva JM, Jimenez-Rodriguez BM, et al. Suicidal ideation and the risk of suicide in patients with fibromyalgia: a comparison with non-pain controls and patients suffering from low-back pain. Neuropsychiatr Dis Treat. 2014;10:625–30.PubMedPubMedCentral
93.
Ilgen MA, Kleinberg F, Ignacio RV, et al. Noncancer pain conditions and risk of suicide. JAMA Psychiatry. 2013;70:692–7.PubMedCrossRef
94.
de Oliveira Ribeiro NP, de Mello Schier AR, Ornelas AC, et al. Anxiety, depression and suicidal ideation in patients with rheumatoid arthritis in use of methotrexate, hydroxychloroquine, leflunomide and biological drugs. Compr Psychiatry. 2013;54:1185–9.CrossRef
95.
Racine M, Choinière M, Nielson WR. Predictors of suicidal ideation in chronic pain patients: an exploratory study. Clin J Pain. 2014;30:371–8.PubMed
96.
97.
Britton PC, Ilgen MA, Valenstein M, et al. Differences between veteran suicides with and without psychiatric symptoms. Am J Public Health. 2012;102 Suppl 1:S125–30.PubMedPubMedCentralCrossRef
98.
Kanzler KE, Bryan CJ, McGeary DD, et al. Suicidal ideation and perceived burdensomeness in patients with chronic pain. Pain Pract. 2012;12:602–9.PubMedCrossRef
99.
100.
Furlanetto LM, Stefanello B. Suicidal ideation in medical inpatients: psychosocial and clinical correlates. Gen Hosp Psychiatry. 2011;33:572–8.PubMedCrossRef
101.
102.
Ilgen MA, Zivin K, Austin KL, et al. Severe pain predicts greater likelihood of subsequent suicide. Suicide Life Threat Behav. 2010;40:597–608.PubMedCrossRef
103.
Braden JB, Sullivan MD. Suicidal thoughts and behavior among adults with self-reported pain conditions in the National Comorbidity Survey Replication. J Pain. 2008;9:1106–15.PubMedPubMedCentralCrossRef
104.
105.
Bolton JM, Cox BJ, Afifi TO, et al. Anxiety disorders and risk for suicide attempts: findings from the Baltimore Epidemiologic Catchment area follow-up study. Depress Anxiety. 2008;25:477–81.PubMedCrossRef
106.
Sareen J, Cox BJ, Afifi TO, et al. Anxiety disorders and risk for suicidal ideation and suicide attempts: a population-based longitudinal study of adults. Arch Gen Psychiatry. 2005;62:1249–57.PubMedCrossRef
107.
Sareen J, Houlahan T, Cox BJ, et al. Anxiety disorders associated with suicidal ideation and suicide attempts in the National Comorbidity Survey. J Nerv Ment Dis. 2005;193:450–4.PubMedCrossRef
108.
Thibodeau MA, Welch PG, Sareen J, et al. Anxiety disorders are independently associated with suicide ideation and attempts: propensity score matching in two epidemiological samples. Depress Anxiety. 2013;30:947–54.PubMedCrossRef
109.
Kamath P, Reddy YC, Kandavel T. Suicidal behavior in obsessive-compulsive disorder. J Clin Psychiatry. 2007;68:1741–50.PubMedCrossRef
110.
Ionescu DF, Luckenbaugh DA, Niciu MJ, et al. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. J Clin Psychiatry. 2014;75:e932–8.PubMedCrossRef
111.
Ionescu DF, Luckenbaugh DA, Niciu MJ, et al. A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. Bipolar Disord. 2015;17:438–43.PubMedCrossRef
112.
Feder A, Parides MK, Murrough JW, et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry. 2014;71:681–8.PubMedCrossRef
113.
Schönenberg M, Reichwald U, Domes G, et al. Ketamine aggravates symptoms of acute stress disorder in a naturalistic sample of accident victims. J Psychopharmacol. 2008;22:493–7.PubMedCrossRef
114.
Schönenberg M, Reichwald U, Domes G, et al. Effects of peritraumatic ketamine medication on early and sustained posttraumatic stress symptoms in moderately injured accident victims. Psychopharmacology (Berl). 2005;182:420–5.CrossRef
115.
Zhang LM, Zhou WW, Ji YJ, et al. Anxiolytic effects of ketamine in animal models of posttraumatic stress disorder. Psychopharmacology (Berl). 2015;232:663–72.CrossRef
116.
Bloch MH, Wasylink S, Landeros-Weisenberger A, et al. Effects of ketamine in treatment-refractory obsessive-compulsive disorder. Biol Psychiatry. 2012;72:964–70.PubMedPubMedCentralCrossRef
117.
Rodriguez CI, Kegeles LS, Levinson A, et al. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology. 2013;38:2475–83.PubMedPubMedCentralCrossRef
118.
Rodriguez CI, Kegeles LS, Levinson A, et al. In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: proof of concept. Psychiatry Res. 2015;233:141–7.PubMedCrossRef
119.
Niciu MJ, Grunschel BD, Corlett PR, et al. Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder. J Psychopharmacol. 2013;27:651–4.PubMedCrossRef
120.
Druss B, Pincus H. Suicidal ideation and suicide attempts in general medical illnesses. Arch Intern Med. 2000;160:1522–6.PubMedCrossRef
121.
Juurlink DN, Herrmann N, Szalai JP, et al. Medical illness and the risk of suicide in the elderly. Arch Intern Med. 2004;164:1179–84.PubMedCrossRef
122.
Moitra VK, Patel MK, Darrah D, et al. Low-dose ketamine in chronic critical illness. J Intensive Care Med. 2015.
123.
Irwin SA, Iglewicz A. Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care. J Palliat Med. 2010;13:903–8.PubMedPubMedCentralCrossRef
124.
Insel TR. The NIMH Research Domain Criteria (RDoC) Project: precision medicine for psychiatry. Am J Psychiatry. 2014;171:395–7.PubMedCrossRef
125.
Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56:893–7.PubMedCrossRef
126.
Ameil R, Luckenbaugh DA, Gould NF, et al. SHAPS-C: The Snaith-Hamilton Pleasure Scale modified for clinician administration. Peer J. 2014;2:e429. PrePrints.CrossRef
127.
Fawcett J, Scheftner WA, Fogg L, et al. Time-related predictors of suicide in major affective disorder. Am J Psychiatry. 1990;147:1189–94.PubMedCrossRef
128.
Loas G, Fremaux D, Gayant C, et al. Anhedonia, depression, and suicidal ideation. Percept Mot Skills. 1995;80:978.PubMedCrossRef
129.
Loas G. Anhedonia and suicide: a 6.5-yr. follow-up study of patients hospitalised for a suicide attempt. Psychol Rep. 2007;100:183–90.PubMedCrossRef
130.
Oei TI, Verhoeven WM, Westenberg HG, et al. Anhedonia, suicide ideation and dexamethasone nonsuppression in depressed patients. J Psychiatr Res. 1990;24:25–35.PubMedCrossRef
131.
Nutt D, Demyttenaere K, Janka Z, et al. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J Psychopharmacol. 2007;21:461–71.PubMedCrossRef
132.
Opbroek A, Delgado PL, Laukes C, et al. Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses? Int J Neuropsychopharmacol. 2002;5:147–51.PubMedCrossRef
133.
Donahue RJ, Muschamp JW, Russo SJ, et al. Effects of striatal ΔFosB overexpression and ketamine on social defeat stress-induced anhedonia in mice. Biol Psychiatry. 2014;76:550–8.PubMedPubMedCentralCrossRef
134.
Lally N, Nugent AC, Luckenbaugh DA, et al. Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Transl Psychiatry. 2014;4:e469.PubMedPubMedCentralCrossRef
135.
Lally N, Nugent AC, Luckenbaugh DA, et al. Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. J Psychopharmacol. 2015;29:596–607.PubMedCrossRef
136.
Garcia LS, Comim CM, Valvassori SS, et al. Ketamine treatment reverses behavioral and physiological alterations induced by chronic mild stress in rats. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:450–5.PubMedCrossRef
137.
Weissman A, Beck A, Kovacs M. Drug abuse, hopelessness, and suicidal behavior. Int J Addict. 1979;14:451–64.PubMedCrossRef
138.
Emery G, Steer R, Beck A. Depression, hopelessness, and suicidal intent among heroin addicts. Int J Addict. 1981;16:425–9.PubMedCrossRef
139.
Beck AT, Steer RA, Kovacs M, et al. Hopelessness and eventual suicide: a 10-year prospective study of patients hospitalized with suicidal ideation. Am J Psychiatry. 1985;142:559–63.PubMedCrossRef
140.
Chochinov HM, Wilson KG, Enns M, et al. Depression, hopelessness, and suicidal ideation in the terminally ill. Psychosomatics. 1998;39:366–70.PubMedCrossRef
141.
Hewitt P, Norton G, Flett G, et al. Dimensions of perfectionism, hopelessness, and attempted suicide in a sample of alcoholics. Suicide Life Threat Behav. 1998;28:395–406.PubMed
142.
Borges G, Saltijeral MT, Bimbela A, et al. Suicide attempts in a sample of patients from a general hospital. Arch Med Res. 2000;31:366–72.PubMedCrossRef
143.
Papakostas GI, Petersen T, Pava J, et al. Hopelessness and suicidal ideation in outpatients with treatment-resistant depression: prevalence and impact on treatment outcome. J Nerv Ment Dis. 2003;191:444–9.PubMedCrossRef
144.
Fawcett J, Scheftner W, Clark D, et al. Clinical predictors of suicide in patients with major affective disorders: a controlled prospective study. Am J Psychiatry. 1987;144:35–40.PubMedCrossRef
145.
Young MA, Fogg LF, Scheftner W, et al. Stable trait components of hopelessness: baseline and sensitivity to depression. J Abnorm Psychol. 1996;105:155–65.PubMedCrossRef
146.
Samuelsson M, Jokinen J, Nordström AL, et al. CSF 5-HIAA, suicide intent and hopelessness in the prediction of early suicide in male high-risk suicide attempters. Acta Psychiatr Scand. 2006;113:44–7.PubMedCrossRef
147.
Brezo J, Paris J, Turecki G. Personality traits as correlates of suicidal ideation, suicide attempts, and suicide completions: a systematic review. Acta Psychiatr Scand. 2006;113:180–206.PubMedCrossRef
148.
Chan S, Miranda R, Surrence K. Subtypes of rumination in the relationship between negative life events and suicidal ideation. Arch Suicide Res. 2009;13:123–35.PubMedCrossRef
149.
Miranda R, Nolen-Hoeksema S. Brooding and reflection: rumination predicts suicidal ideation at 1-year follow-up in a community sample. Behav Res Ther. 2007;45:3088–95.PubMedPubMedCentralCrossRef
150.
Miranda R, Valderrama J, Tsypes A, et al. Cognitive inflexibility and suicidal ideation: mediating role of brooding and hopelessness. Psychiatry Res. 2013.
151.
Morrison R, O’Connor RC. A systematic review of the relationship between rumination and suicidality. Suicide Life Threat Behav. 2008;38:523–38.PubMedCrossRef
152.
Surrence K, Miranda R, Marroquín BM, et al. Brooding and reflective rumination among suicide attempters: cognitive vulnerability to suicidal ideation. Behav Res Ther. 2009;47:803–8.PubMedCrossRef
153.
Scheidegger M, Walter M, Lehmann M, et al. Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action. PLoS ONE. 2012;7:e44799.PubMedPubMedCentralCrossRef
154.
Hamilton JP, Furman DJ, Chang C, et al. Default-mode and task-positive network activity in major depressive disorder: implications for adaptive and maladaptive rumination. Biol Psychiatry. 2011;70:327–33.PubMedPubMedCentralCrossRef
155.
Dalca IM, McGirr A, Renaud J, et al. Gender-specific suicide risk factors: a case-control study of individuals with major depressive disorder. J Clin Psychiatry. 2013;74:1209–16.PubMedCrossRef
156.
Doihara C, Kawanishi C, Yamada T, et al. Trait aggression in suicide attempters: a pilot study. Psychiatry Clin Neurosci. 2008;62:352–4.PubMedCrossRef
157.
Galfalvy H, Oquendo MA, Carballo JJ, et al. Clinical predictors of suicidal acts after major depression in bipolar disorder: a prospective study. Bipolar Disord. 2006;8:586–95.PubMedCrossRef
158.
Keilp JG, Gorlyn M, Oquendo MA, et al. Aggressiveness, not impulsiveness or hostility, distinguishes suicide attempters with major depression. Psychol Med. 2006;36:1779–88.PubMedCrossRef
159.
Koller G, Preuss U, Bottlender M, et al. Impulsivity and aggression as predictors of suicide attempts in alcoholics. Eur Arch Psychiatry Clin Neurosci. 2002;252:155–60.PubMedCrossRef
160.
McGirr A, Paris J, Lesage A, et al. Risk factors for suicide completion in borderline personality disorder: a case-control study of cluster B comorbidity and impulsive aggression. J Clin Psychiatry. 2007;68:721–9.PubMedCrossRef
161.
Monkul ES, Hatch JR, Peluso MAM, et al. Suicide attempts and hostility in major depression. Biol Psychiatry. 2007;61:281.
162.
Oquendo MA, Bongiovi-Garcia ME, Galfalvy H, et al. Sex differences in clinical predictors of suicidal acts after major depression: a prospective study. Am J Psychiatry. 2007;164:134–41.PubMedPubMedCentralCrossRef
163.
Pompili M, Innamorati M, Raja M, et al. Suicide risk in depression and bipolar disorder: do impulsiveness-aggressiveness and pharmacotherapy predict suicidal intent? Neuropsychiatr Dis Treat. 2008;4:247–55.PubMedPubMedCentralCrossRef
164.
Bachenberg KL. Oral ketamine for the management of combative autistic adult. Anesthesiology. 1998;89:549–50.PubMedCrossRef
165.
Donoghue AC, Roback MG, Cullen KR. Remission from behavioral dysregulation in a child with PTSD after receiving procedural ketamine. Pediatrics. 2015.
166.
Roberts JR, Geeting GK. Intramuscular ketamine for the rapid tranquilization of the uncontrollable, violent, and dangerous adult patient. J Trauma. 2001;51:1008–10.PubMedCrossRef
167.
Takahashi RN, Morato GS, Monteiro-de-Lima TC. Effects of ketamine on experimental animal models of aggression. Braz J Med Biol Res. 1984;17:171–8.PubMed
168.
169.
Raust A, Slama F, Mathieu F, et al. Prefrontal cortex dysfunction in patients with suicidal behavior. Psychol Med. 2007;37:411–9.PubMedCrossRef
170.
Xie W, Li H, Luo X, et al. Anhedonia and pain avoidance in the suicidal mind: behavioral evidence for motivational manifestations of suicidal ideation in patients with major depressive disorder. J Clin Psychol. 2014;70:681–92.PubMedCrossRef
171.
Zouk H, Tousignant M, Seguin M, et al. Characterization of impulsivity in suicide completers: clinical, behavioral and psychosocial dimensions. J Affect Disord. 2006;92:195–204.PubMedCrossRef
172.
Dombrovski AY, Szanto K, Siegle GJ, et al. Lethal forethought: delayed reward discounting differentiates high- and low-lethality suicide attempts in old age. Biol Psychiatry. 2011;70:138–44.PubMedPubMedCentralCrossRef
173.
Dombrovski AY, Szanto K, Clark L, et al. Reward signals, attempted suicide, and impulsivity in late-life depression. JAMA Psychiatry. 2013;70:1.PubMedCrossRef
174.
Vanyukov PM, Szanto K, Hallquist MN, et al. Paralimbic and lateral prefrontal encoding of reward value during intertemporal choice in attempted suicide. Psychol Med. 2015;46:1–11.
175.
Cottone P, Iemolo A, Narayan AR, et al. The uncompetitive NMDA receptor antagonists ketamine and memantine preferentially increase the choice for a small, immediate reward in low-impulsive rats. Psychopharmacology (Berl). 2013;226:127–38.CrossRef
176.
Francois J, Grimm O, Schwarz AJ, et al. Ketamine suppresses the ventral striatal response to reward anticipation: a cross-species translational neuroimaging study. Neuropsychopharmacology. 2015.
177.
Lv Q, Yang L, Li G, et al. Large-scale persistent network reconfiguration induced by ketamine in anesthetized monkeys: relevance to mood disorders. Biol Psychiatry. 2015.
178.
Keilp JG, Sackeim HA, Brodsky BS, et al. Neuropsychological dysfunction in depressed suicide attempters. Am J Psychiatry. 2001;158:735–41.PubMedCrossRef
179.
180.
Keilp JG, Gorlyn M, Russell M, et al. Neuropsychological function and suicidal behavior: attention control, memory and executive dysfunction in suicide attempt. Psychol Med. 2013;43:539–51.PubMedPubMedCentralCrossRef
181.
Mathew SJ, Murrough JW. aan het Rot M, et al.: Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol. 2010;13:71–82.PubMedCrossRef
182.
Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170:1134–42.PubMedPubMedCentralCrossRef
183.
Murrough JW, Perez AM, Pillemer S, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013;74:250–6.PubMedPubMedCentralCrossRef
184.
Shiroma PR, Albott CS, Johns B, et al. Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression. Int J Neuropsychopharmacol. 2014;17:1805–13.PubMedCrossRef
185.
Murrough JW, Burdick KE, Levitch CF, et al. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial. Neuropsychopharmacology. 2015;40:1084–90.PubMedPubMedCentralCrossRef
186.
Cunningham WA, Preacher KJ, Banaji MR. Implicit attitude measures: consistency, stability, and convergent validity. Psychol Sci. 2001;12:163–70.PubMedCrossRef
187.
Banse R, Seise J, Zerbes N. Implicit attitudes towards homosexuality: reliability, validity, and controllability of the IAT. Z Exp Psychol. 2001;48:145–60.PubMedCrossRef
188.
Gabriel U, Banse R, Hug F. Predicting private and public helping behaviour by implicit attitudes and the motivation to control prejudiced reactions. Br J Soc Psychol. 2007;46:365–82.PubMedCrossRef
189.
Greenwald AG, Poehlman TA, Uhlmann EL, et al. Understanding and using the Implicit Association Test: III. Meta-analysis of predictive validity. J Pers Soc Psychol. 2009;97:17–41.PubMedCrossRef
190.
Bernert RA, Joiner TE. Sleep disturbances and suicide risk: a review of the literature. Neuropsychiatr Dis Treat. 2007;3:735.PubMedPubMedCentral
191.
Sjöström N, Hetta J, Waern M. Persistent nightmares are associated with repeat suicide attempt: a prospective study. Psychiatry Res. 2009;170:208–11.PubMedCrossRef
192.
Bjørngaard JH, Bjerkeset O, Romundstad P, et al. Sleeping problems and suicide in 75,000 Norwegian adults: a 20 year follow-up of the HUNT I study. Sleep. 2011;34:1155–9.PubMedPubMedCentral
193.
Blasco-Fontecilla H, Alegria AA, Lopez-Castroman J, et al. Short self-reported sleep duration and suicidal behavior: a cross-sectional study. J Affect Disord. 2011;133:239–46.PubMedCrossRef
194.
McCall WV, Blocker JN, D’Agostino R, et al. Insomnia severity is an indicator of suicidal ideation during a depression clinical trial. Sleep Med. 2010;11:822–7.PubMedPubMedCentralCrossRef
195.
Tanskanen A, Tuomilehto J, Viinamäki H, et al. Nightmares as predictors of suicide. Sleep. 2001;24:844–7.PubMed
196.
Wong MM, Brower KJ. The prospective relationship between sleep problems and suicidal behavior in the National Longitudinal Study of Adolescent Health. J Psychiatr Res. 2012;46:953–9.PubMedPubMedCentralCrossRef
197.
Duncan WC, Sarasso S, Ferrarelli F, et al. Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int J Neuropsychopharmacol. 2013;16:301–11.PubMedPubMedCentralCrossRef
198.
Duncan WC, Selter J, Brutsche N, et al. Baseline delta sleep ratio predicts acute ketamine mood response in major depressive disorder. J Affect Disord. 2013;145:115–9.PubMedPubMedCentralCrossRef
199.
Duncan WC, Zarate CA. Ketamine, sleep, and depression: current status and new questions. Curr Psychiatry Rep. 2013;15:394.PubMedCrossRef
200.
Hunt IM, Kapur N, Robinson J, et al. Suicide within 12 months of mental health service contact in different age and diagnostic groups. National clinical survey. Br J Psychiatry. 2006;188:135–42.PubMedCrossRef
201.
Meehan J, Kapur N, Hunt IM, et al. Suicide in mental health in-patients and within 3 months of discharge. National clinical survey. Br J Psychiatry. 2006;188:129–34.PubMedCrossRef
202.
Olié E, Guillaume S, Jaussent I, et al. Higher psychological pain during a major depressive episode may be a factor of vulnerability to suicidal ideation and act. J Affect Disord. 2010;120:226–30.PubMedCrossRef
203.
Rasmussen KG, Lineberry TW, Galardy CW, et al. Serial infusions of low-dose ketamine for major depression. J Psychopharmacol. 2013;27:444–50.PubMedCrossRef
204.
Conrad AK, Jacoby AM, Jobes DA, et al. A psychometric investigation of the Suicide Status Form II with a psychiatric inpatient sample. Suicide Life Threat Behav. 2009;39:307–20.PubMedCrossRef
205.
Diamond PR, Farmery AD, Atkinson S, et al. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. J Psychopharmacol. 2014;28:536–44.PubMedCrossRef
206.
207.
Beck A, Steer R. Clinical predictors of eventual suicide: a 5- to 10-year prospective study of suicide attempters. J Affect Disord. 1989;17:203–9.PubMedCrossRef
208.
Beck AT, Brown G, Steer RA. Prediction of eventual suicide in psychiatric inpatients by clinical ratings of hopelessness. J Consult Clin Psychol. 1989;57:309–10.PubMedCrossRef
209.
Brent DA, Oquendo M, Birmaher B, et al. Familial transmission of mood disorders: convergence and divergence with transmission of suicidal behavior. J Am Acad Child Adolesc Psychiatry. 2004;43:1259–66.PubMedCrossRef
210.
Goldston DB, Daniel SS, Reboussin BA, et al. Cognitive risk factors and suicide attempts among formerly hospitalized adolescents: a prospective naturalistic study. J Am Acad Child Adolesc Psychiatry. 2001;40:91–9.PubMedCrossRef
211.
Holma K, Melartin T, Haukka J, et al. Incidence and predictors of suicide attempts in DSM-IV major depressive disorder: a five-year prospective study. Am J Psychiatry. 2010;167:801–8.PubMedCrossRef
212.
Marangell LB, Bauer MS, Dennehy EB, et al. Prospective predictors of suicide and suicide attempts in 1,556 patients with bipolar disorders followed for up to 2 years. Bipolar Disord. 2006;8:566–75.PubMedCrossRef
213.
Sidley GL, Calam R, Wells A, et al. The prediction of parasuicide repetition in a high-risk group. Br J Clin Psychol. 1999;38(Pt 4):375–86.PubMedCrossRef
214.
Ribeiro JD, Pease JL, Gutierrez PM, et al. Sleep problems outperform depression and hopelessness as cross-sectional and longitudinal predictors of suicidal ideation and behavior in young adults in the military. J Affect Disord. 2012;136:743–50.PubMedCrossRef
215.
Sokero TP, Melartin TK, Rytsälä HJ, et al. Prospective study of risk factors for attempted suicide among patients with DSM-IV major depressive disorder. Br J Psychiatry. 2005;186:314–8.PubMedCrossRef
216.
Young MA, Fogg LF, Scheftner WA, et al. Interactions of risk factors in predicting suicide. Am J Psychiatry. 1994;151:434–5.PubMedCrossRef
Metadata
Title
Ketamine for Treatment of Suicidal Ideation and Reduction of Risk for Suicidal Behavior
Authors
Faryal Mallick
Cheryl B. McCullumsmith
Publication date
01-06-2016
Publisher
Springer US
Published in
Current Psychiatry Reports / Issue 6/2016
Print ISSN: 1523-3812
Electronic ISSN: 1535-1645
DOI
https://doi.org/10.1007/s11920-016-0680-7

Other articles of this Issue 6/2016

Current Psychiatry Reports 6/2016 Go to the issue

Child and Family Disaster Psychiatry (B Pfefferbaum, Section Editor)

Determinants of Children’s Mental Health in War-Torn Settings: Translating Research Into Action

Eating Disorders (C Grilo, Section Editor)

Combining Pharmacological and Psychological Treatments for Binge Eating Disorder: Current Status, Limitations, and Future Directions

Child and Family Disaster Psychiatry (B Pfefferbaum, Section Editor)

Public Disaster Communication and Child and Family Disaster Mental Health: a Review of Theoretical Frameworks and Empirical Evidence

Child and Family Disaster Psychiatry (B Pfefferbaum, Section Editor)

The Role of Parents, Parenting and the Family Environment in Children’s Post-Disaster Mental Health

Women's Mental Health (CN Epperson, Section Editor)

Depression and Anxiety During Pregnancy: Evaluating the Literature in Support of Clinical Risk-Benefit Decision-Making

Geriatric Disorders (W McDonald, Section Editor)

The Mental Health of Older LGBT Adults